<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Telomere Dysfunction-Associated Neurons</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TTAGGG repeats</td>
<td>Repetitive DNA sequences</td>
</tr>
<tr>
<td class="label">Shelterin complex</td>
<td>Protein complex protecting telomeres</td>
</tr>
<tr>
<td class="label">TERT</td>
<td>Telomerase reverse transcriptase</td>
</tr>
<tr>
<td class="label">TERC</td>
<td>Telomerase RNA component</td>
</tr>
<tr>
<td class="label">TRF1/TRF2</td>
<td>Telomeric repeat binding factors</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Telomere Findings</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Variable changes, genetic modifiers</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Shortened telomeres in some cohorts</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Accelerated shortening in progressive forms</td>
</tr>
<tr>
<td class="label">FTD-ALS Spectrum</td>
<td>Complex patterns by subtype</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cyclophosphamide vs.</td>
<td>Low-dose effects</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label"
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Telomere Dysfunction-Associated Neurons</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TTAGGG repeats</td>
<td>Repetitive DNA sequences</td>
</tr>
<tr>
<td class="label">Shelterin complex</td>
<td>Protein complex protecting telomeres</td>
</tr>
<tr>
<td class="label">TERT</td>
<td>Telomerase reverse transcriptase</td>
</tr>
<tr>
<td class="label">TERC</td>
<td>Telomerase RNA component</td>
</tr>
<tr>
<td class="label">TRF1/TRF2</td>
<td>Telomeric repeat binding factors</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Telomere Findings</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Variable changes, genetic modifiers</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Shortened telomeres in some cohorts</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Accelerated shortening in progressive forms</td>
</tr>
<tr>
<td class="label">FTD-ALS Spectrum</td>
<td>Complex patterns by subtype</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Cyclophosphamide vs.</td>
<td>Low-dose effects</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Reduce oxidative stress</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>SIRT1/TERT activation</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TERT</td>
<td>Telomerase catalytic subunit</td>
</tr>
<tr>
<td class="label">TERC</td>
<td>Telomerase RNA</td>
</tr>
<tr>
<td class="label">DKC1</td>
<td>Dyskerin, telomerase assembly</td>
</tr>
<tr>
<td class="label">RTEL1</td>
<td>Helicase, telomere maintenance</td>
</tr>
<tr>
<td class="label">POT1</td>
<td>Shelterin component</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Potential Use</td>
</tr>
<tr>
<td class="label">Risk prediction</td>
<td>Identify at-risk individuals</td>
</tr>
<tr>
<td class="label">Disease progression</td>
<td>Marker of aging rate</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Pharmacodynamic marker</td>
</tr>
<tr>
<td class="label">Prognosis</td>
<td>Outcome prediction</td>
</tr>
</table>
Telomere Dysfunction Associated [Neurons](/entities/neurons) is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Telomere shortening and dysfunction in neurons represent fundamental mechanisms of cellular aging and have been increasingly recognized as contributors to neurodegenerative processes in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, and other disorders. This page examines the relationship between telomere biology and neuronal health in neurodegeneration. [@eitan2021]
Telomeres are specialized DNA-protein structures that protect chromosome ends from degradation and fusion. In post-mitotic neurons, telomere maintenance is crucial for: [@ferrer2020]
Unlike proliferating cells, neurons face unique challenges:
Multiple studies have demonstrated telomere abnormalities in AD:
Peripheral Telomere Findings:
Similar telomere findings in PD:
Clinical Evidence:
Telomere biology in ALS shows complex patterns:
Findings:
Telomere dysfunction triggers DNA damage responses:
Telomere-mitochondria crosstalk in neurons:
Telomere shortening induces senescence:
Small Molecule Activators:
Instead of directly lengthening telomeres:
Peripheral Measurements:
Telomere dysfunction represents a fundamental mechanism of neuronal aging with clear associations to multiple neurodegenerative diseases. While direct telomere lengthening remains experimental, understanding telomere biology provides insights into disease mechanisms and identifies potential therapeutic targets. The complex relationship between telomere status and neurodegeneration requires continued research to translate findings into clinical applications.
The study of Telomere Dysfunction Associated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving Telomere Dysfunction-Associated Neurons discovered through SciDEX knowledge graph analysis: